Why the ResApp (ASX:RAP) share price is sinking 5% today

The ResApp (ASX: RAP) share price is sinking today despite a positive announcement made to the ASX market. Here's the latest.

| More on:
falling asx share price represented by woman making sad face

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResApp Health Ltd (ASX: RAP) share price is sinking today. This comes after the company announced that Medgate had started European trails for ResAppDx, its smartphone-based acute respiratory diagnostic test.

At the time of writing, the digital health company's shares are down 6.78%, trading at 5.5 cents.

First, a quick take on Medgate

Founded in 1999, Medgate provides telehealth services, bringing physicians to patients where needed via digital health bookings.

The company operates Europe's largest telemedical centre in Switzerland and employs more than 500 people worldwide. Medgate has a presence in Germany, the Philippines, the United Arab Emirates, and India.

Why is the ResApp share price moving?

In today's release, ResApp advised that Medgate has begun a 3-month pilot trial of ResAppDx through its telemedicine services in Switzerland. This follows a joint development and pilot agreement the companies signed in November last year.

During the initial phase of the partnership, both companies conducted detailed technical reviews on the ResAppDx technology. This included creating roadmaps for patients with respiratory disease symptoms, usability testing, automated processes, and training material development.

The companies will jointly evaluate the ResAppDx platform rollout across Medigate's telehealth service. Several key metrics will be applied as a benchmark to test its success.

They will finalise negotiations on the cost model of the integration once ResAppDx passes the pilot trial.

Management commentary

ResApp CEO and managing director, Dr Tony Keating, commented:

…We are very confident that ResAppDx will provide considerable benefits for Medgate patients, physicians and insurers.

Medgate has made a strong commitment to ResApp and both parties remain confident of a successful pilot trial. The company has already significantly benefitted from Medgate's knowledge and insights into telehealth best practice, and we look forward to continuing this work into the future.

Medgate CEO, Dr Andy Fisher, added:

We are absolutely convinced that the use of new technologies like ResAppDx will enable an advancement of our Digital Health platform. This will benefit our patients by enabling them to be treated conclusively by phone or video in even more cases.

ResApp share price review

The ResApp share price has been a weak performer over the past 12 months, declining more than 65%. The company's shares hit a multi-year low of 5.2 cents last month and are within striking distance today, at 5.5 cents.

Should you invest $1,000 in Resapp Health right now?

Before you buy Resapp Health shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Resapp Health wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Excited couple celebrating success while looking at smartphone.
Broker Notes

Bell Potter names the best ASX 200 stocks to buy in May

The broker is feeling bullish on these names this month. Let's find out why.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
Opinions

Investing in high-yield ASX stocks has two major negatives

High-yield stocks do have downsides.

Read more »

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy finish to the week for ASX shares this Friday.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A mature age woman with a groovy short haircut and glasses, sits at her computer, pen in hand thinking about information she is seeing on the screen.
Share Market News

ASX shares in April: 8 key takeaways according to Macquarie

Here are eight key takeaways from April, according to a new note from the broker.

Read more »

Woman looking at a phone with stock market bars in the background.
Share Market News

Market outlook: Should I 'sell in May and go away'?

May is the time to sell... If you believe in fairytales.

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
Share Gainers

5 ASX All Ords stocks rocketing higher this week

Investors sent these five ASX All Ords stocks soaring this week. But why?

Read more »